MedTrace Logo

Personalized Medicine for Diabetes Prediction and Prevention of Complications

NCT01268813 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-12-31

No results posted yet for this study

Summary

The metabolic syndrome is a collection of related risk factors that predispose to the development of type 2 diabetes Mellitus and cardiovascular disease. The investigators will examine the hypothesis that the metabolic and genomic characteristics of patients with metabolic syndrome and/or diabetes that are at risk for developing complications differ from each other and can be detected using specific biomarkers in blood or in the exhaled breath. Early detection of these individuals will enable personalized treatment to prevent and treat diabetes and its complications

Conditions

Interventions

OTHER

Breath analysis and blood analysis

Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.

Sponsors & Collaborators

  • Technion, Israel Institute of Technology

    collaborator OTHER

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Eddy Karnieli, MD · Rambam Medicl Center, Technion

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-12-31
Completion
2013-03-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01268813 on ClinicalTrials.gov